Raphael Pharmaceutical (RAPH) Non Operating Income (2020 - 2026)
Raphael Pharmaceutical's (RAPH) quarterly Non Operating Income came in at -$24000.0 in Q2 2026, down 242.86% year-over-year from $16800.0 in Q2 2025, and down 242.86% quarter-over-quarter from -$7000.0 in Q2 2025.
Powered by 
Analysis
Raphael Pharmaceutical (RAPH) Non Operating Income (2020 - 2026) Analysis & Trends
Raphael Pharmaceutical has disclosed Non Operating Income across 7 years of filings, most recently posting -$24000.0 for Q2 2026.
- In Q2 2026, Non Operating Income fell 242.86% year-over-year to -$24000.0; the TTM figure through Jun 2026 stood at -$39000.0 (down 178.57% YoY), while the FY2025 annual figure was -$34000.0, down 240.0% from the prior year.
- Non Operating Income came in at -$24000.0 for Q2 2026 at Raphael Pharmaceutical, down from -$7000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $4000.0 in Q3 2023 to a low of -$24000.0 in Q2 2026.
- Average Non Operating Income over 5 years is -$6714.3, with a median of -$6500.0 recorded in 2023.
- The largest YoY upside for Non Operating Income was 123.53% in 2023 against a maximum downside of 1300.0% in 2023.
- Over 5 years, Non Operating Income stood at $1000.0 in 2022, then sank by 1300.0% to -$12000.0 in 2023, then soared by 91.67% to -$1000.0 in 2024, then slumped by 600.0% to -$7000.0 in 2025, then sank by 242.86% to -$24000.0 in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were -$24000.0 in Q2 2026, -$7000.0 in Q2 2025, and -$1000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | -24,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -3,000.00 |
| Dec 31, 2023 | -12,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | -6,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -17,000.00 |
| Jun 30, 2022 | -15,000.00 |
| Mar 31, 2022 | -10,000.00 |
| Dec 31, 2021 | 7,000.00 |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | -3,000.00 |
| Dec 31, 2020 | -3,000.00 |